Discovery Goes From the Lab to the Patient, University of North Carolina School of Medicine Study

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

A laboratory testing kit that estimates the risk of breast cancer relapse in spite of anti-hormone treatment has received approval from the U.S. Food and Drug Administration (FDA). This technology is based on a gene signature known as "PAM50" originally discovered at UNC Lineberger Comprehensive Cancer Center by Chuck Perou, PhD, professor of genetics and pathology and UNC Lineberger member. Additional UNC inventors included Dr. Joel Parker, research assistant professor of genetics, and Dr. Maggie Cheang, a research associate in the Perou Lab.

Hey, check out all the engineering jobs. Post your resume today!

Back to news